<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559165</url>
  </required_header>
  <id_info>
    <org_study_id>Dh09066063</org_study_id>
    <nct_id>NCT04559165</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sericin and Chitosan Cream for Preventing and Limiting the Progressive of Pressure Sore</brief_title>
  <official_title>Efficacy and Safety of Sericin and Chitosan Cream for Preventing and Limiting the Progressive of Pressure Sore</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Police General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate efficacy and safety of sericin and chitosan cream for preventing and limiting the&#xD;
      progressive of pressure sore in 20 patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">June 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pressure ulcer scale for healing</measure>
    <time_frame>21 days</time_frame>
    <description>Score 0 to 17, higher scores mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema index</measure>
    <time_frame>21 days</time_frame>
    <description>Erythema index will be measured using Cutometer (Mexameter). There is no unit. Higher value mean higher risk of post inflammatory reaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Melanin index</measure>
    <time_frame>21 days</time_frame>
    <description>Melanin index will be measured using Cutometer (Mexameter). There is no unit. Higher value mean higher risk of post inflammatory reaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transepidermal water loss</measure>
    <time_frame>21 days</time_frame>
    <description>Transepidermal water loss index of skin will be measured using Cutometer (Tewameter). There is no unit. Higher value mean higher risk of unhealthy skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moisture index</measure>
    <time_frame>21 days</time_frame>
    <description>Moisture index of skin will be measured using Cutometer (Corneometer). There is no unit. Higher value mean lower risk of unhealthy skin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>21 days</time_frame>
    <description>Adverse events will be observed. They will be recorded as &quot;present&quot; or &quot;not present&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pressure Ulcer</condition>
  <arm_group>
    <arm_group_label>sericin and chitosan cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apply sericin and chitosan cream on pressure ulcer 2 times/day for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavilon cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apply cavilon cream on pressure ulcer 2 times/day for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sericin and chitosan cream</intervention_name>
    <description>sericin and chitosan cream</description>
    <arm_group_label>Cavilon cream</arm_group_label>
    <arm_group_label>sericin and chitosan cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age more than 18 years old&#xD;
&#xD;
          -  2-digit Stirling Pressure Sore Severity Scale less than or equal to 2.4&#xD;
&#xD;
          -  No chitosan, sericin, and dimethicone allergy&#xD;
&#xD;
          -  Without skin diseases&#xD;
&#xD;
          -  Without Autoimmune diseases&#xD;
&#xD;
          -  Willingness to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have uncontrolled diseases&#xD;
&#xD;
          -  Have complication or adverse effects during the time of participation&#xD;
&#xD;
          -  Cannot follow protocol&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Participate in other study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pornanong Aramwit, Ph.D</last_name>
    <phone>+66899217255</phone>
    <email>aramwit@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn Unviersity</name>
      <address>
        <city>Bangkok</city>
        <zip>10310</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pornanong Aramwit, Ph.D.</last_name>
      <phone>+6689-921-7255</phone>
      <email>aramwit@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pornanong Aramwit, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>September 19, 2020</last_update_submitted>
  <last_update_submitted_qc>September 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Pornanong Aramwit, Pharm.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pressure Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chitosan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

